Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 12:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 15,041 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Results available

Stress CT Perfusion in Patients With Chest Pain

NCT01969916
Conditions
Coronary Artery Disease
Interventions
Regadenoson
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Multiple Myeloma
Interventions
Isatuximab, Bendamustine, Prednisone
Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
HIV Infections
Interventions
Pravastatin, Gemfibrozil, Rosiglitazone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Stroke, Multiple Sclerosis
Interventions
Visuomotor leg reaching task
Behavioral
Lead sponsor
Texas Woman's University
Other
Eligibility
21 Years to 90 Years
Enrollment
130 participants
Timeline
2013 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma
Interventions
Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
28
States / cities
Alabaster, Alabama • Surprise, Arizona • Berkeley, California + 25 more
Conditions
Brain Injuries, Intracranial Pressure Increase, Monitoring
Interventions
Intracranial Pressure Noninvasive Monitoring
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Interventions
INV-102
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Macular Degeneration
Interventions
pazopanib eye drops, Ketoconozole tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Stroke, Aphasia
Interventions
Schedule of tDCS administration
Device
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
West Orange, New Jersey • Milwaukee, Wisconsin
Completed Not applicable Interventional Results available

Dietary Approaches to Stop Hypertension for Diabetes

NCT04286555
Conditions
Diabetes Mellitus, Type 2, Diabetes, Diabetes type2, Type2 Diabetes, Type 2 Diabetes, Type II Diabetes, Hypertension, High Blood Pressure
Interventions
DASH4D diet, comparison diet, higher sodium, lower sodium
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Chronic Wounds, Diabetes, Venous Stasis Ulcers
Interventions
FGF-1
Drug
Lead sponsor
Venturis Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Warren, Pennsylvania
Conditions
Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
Interventions
Remigromig, Aflibercept 2.0 mg
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
55
States / cities
Scottsdale, Arizona • Glendale, California • Modesto, California + 34 more
Conditions
Urinary Incontinence, Bladder Dysfunction
Interventions
Fesoterodine Oral Product
Drug
Lead sponsor
Saint Thomas Health
Other
Eligibility
21 Years to 85 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Multiple Myeloma
Interventions
Lenalidomide Induction, Sequential Maintenance Therapy
Drug
Lead sponsor
Cristina Gasparetto
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Terminated Phase 4 Interventional Results available

Alternative in Beta Blocker Intolerance: The ABBI Trial

NCT00893984
Conditions
Coronary Artery Disease
Interventions
Nebivolol
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Whey Protein Effects on Gycemic Control and Vascular Function

NCT01814358
Conditions
Blood Sugar (Glucose) Control, Blood Vessel (Vascular) Dysfunction
Interventions
Whey protein powder, Control protein
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Fabry Disease
Interventions
Venglustat (GZ402671), Agalsidase alfa, Agalsidase beta (GZ419828), Migalastat
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 5 more
Active, not recruiting No phase listed Observational

Motor rECovery witH eArly imagiNg In STroke

NCT04165616
Conditions
Stroke
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Chicago, Illinois
Conditions
Coronary Artery Disease, Death, Myocardial Infarction
Interventions
Not listed
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
18 Years to 90 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
West Roxbury, Massachusetts
Conditions
Hemorrhoid, Hemorrhoid Bleeding
Interventions
Latex Band, Non-Latex Band
Device
Lead sponsor
Huntington Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Pasadena, California
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed Conditions

NCT01013155
Conditions
Essential Hypertension
Interventions
perindopril erbumine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Houston, Texas
Conditions
Stroke
Interventions
human chorionic gonadotropin (hCG), then epoetin alfa (EPO), Saline Placebo
Drug
Lead sponsor
Stem Cell Therapeutics Corp.
Industry
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orange, California
Conditions
Multiple Myeloma
Interventions
Elotuzumab
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Charlotte, North Carolina
Terminated Phase 4 Interventional Results available

Postpartum Hypertension Study

NCT05139238
Conditions
Postpartum Pregnancy-Induced Hypertension, Postpartum Preeclampsia, Pregnancy-Induced Hypertension in Postpartum, Hypertensive Emergency
Interventions
Labetalol, Nifedipine
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York